Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Menée aux Etats-Unis auprès de 120 témoins et 20 patients atteints d'une maladie lymphoproliférative traitée par immunothérapie à base de lymphocytes CAR-T ciblant CD19 (âge médian : 67 ans ; 60 % de femmes), cette étude identifie des facteurs de risque de néoplasme myéloïde lié au traitement
Impressive clinical trial outcomes led to US Food and Drug Administration approval of chimeric antigen receptor T-cell therapy (CART) targeting CD19 for B-cell lymphoproliferative disorders (LPDs) and B-cell maturation antigen for multiple myeloma (MM). The most common CART toxic effect, immune effector cell–associated hematotoxicity (ICAHT), generally resolves by month 3. Myeloid neoplasms occurring after CART (post-CART MN) are also recognized outcomes but with short latency. To inform counseling, risk stratification, and potential surveillance strategies, we report updated incidence and factors associated with post-CART MN events.
JAMA Oncology 2024